C57BL/6NTac-Arhgef4^{tm1a(KOMP)Wtsi}/WtsiCnbc

Status	Under development - register interest
EMMA ID	EM:16706
Citation information	RRID:IMSR_EM:16706 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.
International strain name	C57BL/6NTac-Arhgef4^{tm1a(KOMP)Wtsi}/WtsiCnbc
Alternative name	EPD0135_1_A05
Strain type	Targeted Mutant Strains
Allele/Transgene symbol	Arhgef4^{tm1a(KOMP)Wtsi}
Gene/Transgene symbol	Arhgef4
Disclaimer	Please note that for EUCOMM and KOMP-CSD mice supplied to the scientific community by INFRAFRONTIER/EMMA: We can not guarantee a null mutation for Knock-out first alleles (tm1a alleles, see http://www.mousephenotype.org/about-ikmc/targeting-strategies) as the critical exon has not been deleted. That the structure of the targeted mutation in the ES cells obtained from EUCOMM/KOMP to generate EUCOMM/KOMP mice is not verified by INFRAFRONTIER/EMMA. It is recommended that the recipient confirms the mutation structure. No check for determining the copy number of the targeting construct in ES cells obtained from EUCOMM/KOMP is done by INFRAFRONTIER/EMMA. The level of quality control before mice are released is to confirm the individual mouse genotype by short range PCR.

Information from provider

Provider	Wellcome Trust Sanger Institute
Provider affiliation	Wellcome Trust Sanger Institute
Genetic information	This mouse line originates from KOMP ES clone EPD0135_1_A05. For further details on the construction of this clone see the page at the IMPC portal.
Phenotypic information	Potential phenotyping data in the IMPC portal
References	None available

Information from EMMA

Archiving centre	CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain

Disease and phenotype information

IMPC phenotypes (allele matching)

increased bone mineral density / IMPC
decreased bone mineral density / IMPC
decreased circulating HDL cholesterol level / IMPC
increased circulating calcium level / IMPC
decreased body weight / IMPC
abnormal lens morphology / IMPC
cataract / IMPC
increased circulating free fatty acids level / IMPC
abnormal vibrissa morphology / IMPC
decreased circulating triglyceride level / IMPC
decreased circulating free fatty acids level / IMPC
decreased hemoglobin content / IMPC
increased lactate dehydrogenase level / IMPC
increased circulating alkaline phosphatase level / IMPC
increased lean body mass / IMPC
abnormal behavior / IMPC
decreased T cell number / IMPC
decreased circulating cholesterol level / IMPC
abnormal response to tactile stimuli / IMPC
increased circulating aspartate transaminase level / IMPC
decreased circulating serum albumin level / IMPC
decreased blood urea nitrogen level / IMPC
increased circulating total protein level / IMPC
increased mature B cell number / IMPC
decreased total body fat amount / IMPC

IMPC phenotypes (gene matching)

decreased circulating serum albumin level / IMPC
cataract / IMPC
decreased bone mineral density / IMPC
increased lean body mass / IMPC
increased lactate dehydrogenase level / IMPC
increased circulating total protein level / IMPC
abnormal lens morphology / IMPC
decreased T cell number / IMPC
increased circulating free fatty acids level / IMPC
decreased blood urea nitrogen level / IMPC
decreased hemoglobin content / IMPC
decreased circulating HDL cholesterol level / IMPC
increased circulating calcium level / IMPC
decreased circulating free fatty acids level / IMPC
decreased circulating cholesterol level / IMPC
abnormal vibrissa morphology / IMPC
abnormal response to tactile stimuli / IMPC
abnormal behavior / IMPC
increased mature B cell number / IMPC
decreased total body fat amount / IMPC
increased circulating alkaline phosphatase level / IMPC
increased circulating aspartate transaminase level / IMPC
decreased body weight / IMPC
decreased circulating triglyceride level / IMPC
increased bone mineral density / IMPC

MGI phenotypes (gene matching)

no abnormal phenotype detected / MGI
decreased tumor growth/size / MGI
abnormal tumor morphology / MGI
abnormal vascular endothelial cell migration / MGI
abnormal vascular endothelial cell physiology / MGI
decreased angiogenesis / MGI
abnormal tumor vascularization / MGI

Information on how we integrate external resources can be found here

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.
Not found what you were looking for? Search here for other strains available from EMMA.

C57BL/6NTac-Arhgef4tm1a(KOMP)Wtsi/WtsiCnbc